Skip to main content
OpenTrials
Completed

NCT Number: NCT05607082

COVID-19 Bivalent Booster Megastudy

This megastudy is a massive randomized controlled trial. By randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions to one another and to a control group (in which individuals will only receive the usual communications from their partner organization) to identify which interventions significantly increase vaccination rates. Pharmacy customers will be randomly assigned to receive one of the interventions designed by team scientists to encourage vaccination or to a control group. The baseline intervention will be based on the top-performing SMS intervention identified in the investigators previous megastudies on encouraging vaccination (Milkman et al., 2021b, 2022). Pharmacy customers will receive SMS messages conveying that a COVID booster vaccine is reserved or waiting for them at the pharmacy. Additional behavioral science messaging strategies will be tested by building off of this baseline intervention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient of a large retail pharmacy that has opted into receving SMS messages from the pharmacy and has received their primary COVID vaccination series.

Exclusion criteria

  • The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message
  • The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

Treatment and study plan

COVID Booster text messages

Behavioral

Participants will receive text messages per descriptions listed in the arms.

Primary outcomes

  1. Patient uptake of the COVID bivalent booster

    Time frame: During the 30 days after receiving the SMS/MMS intervention

    Whether patients receive a bivalent COVID booster at the pharmacy in question

Secondary outcomes

  1. Patient uptake of the COVID bivalent booster

    Time frame: 60 days after receiving the SMS/MMS intervention

    Whether patients receive a bivalent COVID booster at the pharmacy in question

  2. Patient uptake of the COVID bivalent booster

    Time frame: 90 days after receiving the SMS/MMS intervention

    Whether patients receive a bivalent COVID booster at the pharmacy in question

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Nov 7, 2022
Registry last updated
Mar 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.